Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Other Financing Activities
Financing cash flows not reported separately.
Solventum CorporationNYSE: SOLV
Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026
Other financing activities grows, but more slowly than its trailing trend
Q2 FY2026 other financing activities of $12M (cash outflow) rose 20.0% year over year, behind the +138.2% change in trailing-twelve-month other financing activities. Sequentially, it fell 58.6% from the prior quarter.
Context
- Other financing activities amounted to 0.2% of revenue in FY2025, down 99.7 pp from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +20.0% toward the trailing-twelve-month pace of +138.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- 13M USD
- Year-over-year change
- +100.2%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13M | +100.2% |
| FY2024 | 2024-12-31 | (8.24B) | -431.1% |
| FY2023 | 2023-12-31 | (1.55B) | -6.3% |
| FY2022 | 2022-12-31 | (1.46B) | +25.5% |
| FY2021 | 2021-12-31 | (1.96B) | — |
Other Financing Activities vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 other financing activities of $21M is the 7th largest of the 10 companies compared; the peer median is $5.6M.
- Its year-over-year change of +138.2% is the 5th highest of 10, against a peer median of -38.8%.
- Other financing activities amounts to 0.3% of revenue for SOLV, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.4B | +4008.0% | — | 16.8% | |
| LTM Jul 2026 | $646.8M | +524.3% | +54.0% | 15.3% | |
| LTM Oct 2026 | $136.2M | +2261.9% | -12.0% | 4.7% | |
| LTM Jun 2026 | $130M | +176.6% | +20.6% | 1.1% | |
| LTM Jun 2026 | $93M | -38.8% | +3.9% | 0.7% | |
| LTM Jun 2026 | $30.14M | -7692.7% | — | 1.4% | |
| LTM Jun 2026 | $21M | +138.2% | — | 0.3% | |
| LTM Sep 2026 | $5.6M | -50.5% | -29.9% | 0.3% | |
| LTM Mar 2026 | $5M | -70.6% | -26.3% | 0.1% | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding SOLV) | $5.6M | -38.8% | -4.0% | 1.1% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| Deferred Income Tax | (34M) | (141M) | (142M) | (155M) | (120M) |
| Stock-Based Compensation | 38M | 37M | 39M | 112M | 161M |
| Change in Working Capital | 67M | (202M) | 126M | 160M | (119M) |
| Accounts Receivables | (1M) | (32M) | (129M) | 276M | 78M |
| Inventory | (136M) | (82M) | 23M | (132M) | (139M) |
| Accounts Payables | 68M | 25M | 105M | 266M | 104M |
| Other Working Capital | 136M | (113M) | 127M | (250M) | (162M) |
| Other Non-Cash Items | 74M | 64M | (15M) | 34M | (1.6B) |
| Operating Cash Flow | 2.2B | 1.68B | 1.92B | 1.19B | 369M |
| Capital Expenditures | (277M) | (251M) | (290M) | (380M) | (379M) |
| Acquisitions (Net) | 0 | 0 | 60M | 0 | (696M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1M) | (2M) | 0 | 0 | 3.87B |
| Investing Cash Flow | (278M) | (253M) | (230M) | (380M) | 2.8B |
| Debt Repayment | 0 | 0 | 0 | 8B | (3.07B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.96B) | (1.46B) | (1.55B) | (8.24B) | 13M |
| Financing Cash Flow | (1.96B) | (1.46B) | (1.55B) | (240M) | (3.06B) |
| Effect of Forex Changes | 3M | 4M | 0 | 3M | 7M |
| Net Change in Cash | (33M) | (30M) | 133M | 568M | 116M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | (10M) |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.